· The diagnosis of Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) must be based on a tissue biopsy. Re-biopsy should be performed at each recurrence when possible. · The new WHO classification of NHL takes into consideration immunophenotype (90% of lymphomas are B-cell origin), cytogenetics and molecular biology. · ″Staging investigations″, i.e. CT scans and a bone marrow aspirate and trephine biopsy, should be performed at presentation and at recurrence to determine the extent and distribution of disease. · Treatment will depend on histological subtype, stage, and the age and performance status of the patient. · Patients with HD, diffuse large B-cell NHL and lymphoblastic lymphoma/Burkitt's lymphoma are treated with curative intent. In other subtypes of NHL, recurrence is virtually inevitable with conventional therapy. · Imaging is essential for staging, assessment of response and in the diagnosis of relapse. Standardized response criteria have been developed, and should be adopted for clinical usage.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging